Energy disruptors: rising stars in anticancer therapy?

Oncogenesis

Volumn 5, Issue 1, 2016, Pages

  Bost, F ^a,b   Decoux Poullot, A G ^a,b   Tanti, J F ^a,b   Clavel, S ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85121351214     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/ONCSIS.2015.46     Document Type: Review

References (89)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309–314.
2. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892–3899.
3. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 1997; 272: 17269–17275.
4. Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015; 519: 477–481.
5. Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant GA, Plovanich ME et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015; 347: 188–194.
6. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013; 339: 1323–1328.
7. Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol 2015; 33: 1–7.
8. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 38–43.
9. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA 2006; 103: 17378–17383.
10. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014; 20: 953–966.
11. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–1174.
12. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
13. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305.
14. Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care 2014; 37: 1786–1788.
15. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576–3586.
16. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269–10273.
17. Dirat B, Ader I, Golzio M, Massa F, Mettouchi A, Laurent K et al. Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. Mol Cancer Ther 2015; 14: 586–596.
18. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539–6545.
19. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685–693.
20. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412: 211–221.
21. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F et al. Metformin blocks melanoma invasion and metastasis development in a AMPK/p53-dependent manner. Mol Cancer Ther 2013; 12: 1605–1615.
22. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745–6752.
23. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011; 2: e199.
24. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223–228.
25. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348(Pt 3): 607–614.
26. Fontaine E. Metformin and respiratory chain complex I: the last piece of the puzzle? Biochem J 2014; 463: e3–e5.
27. Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 2014; 462: 475–487.
28. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465–2475.
29. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 2014; 3: e02242.
30. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355–2369.
31. Loubiere C, Goiran T, Laurent K, Djabari Z, Tanti JF, Bost F. Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget 2015; 6: 15652–15661.
32. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73: 4429–4438.
33. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507–7511.
34. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2010; 71: 3196–3201.
35. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012; 5: 355–364.
36. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127: 390–397.
37. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9: 3807–3814.
38. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M et al. MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 2015; 22: 590–605.
39. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 19: 19.
40. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–10812.
41. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71: 4366–4372.
42. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390–401.
43. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346–350.
44. Pollak N, Dolle C, Ziegler M. The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. Biochem J 2007; 402: 205–218.
45. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, Spitz DR. Simultaneous inhibition of glutathione-and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med 2012; 52: 436–443.
46. Boutros J, Almasan A. Combining 2-deoxy-D-glucose with electron transport chain blockers: a double-edged sword. Cancer Biol Ther 2009; 8: 1237–1238.
47. Schachter H. Complex N-glycans: the story of the ‘yellow brick road’. Glycoconj J 2014; 31: 1–5.
48. Qin JZ, Xin H, Nickoloff BJ. 2-deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose. Biochem Biophys Res Commun 2010; 401: 293–299.
49. Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado OM et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res 2011; 71: 6796–6806.
50. Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res 2005; 65: 7023–7030.
51. Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A et al. Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death Differ 2013; 20: 611–619.
52. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995; 229: 558–565.
53. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134: 405–415.
54. Niederberger E, King TS, Russe OQ, Geisslinger G. Activation of AMPK and its impact on exercise capacity. Sports Med 2015; 45: 1497–1509.
55. Henin N, Vincent MF, Gruber HE, Van den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995; 9: 541–546.
56. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 2002; 12: 1419–1423.
57. Koistinen HA, Galuska D, Chibalin AV, Yang J, Zierath JR, Holman GD et al. 5-Amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 2003; 52: 1066–1072.
58. Pold R, Jensen LS, Jessen N, Buhl ES, Schmitz O, Flyvbjerg A et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005; 54: 928–934.
59. Babraj JA, Mustard K, Sutherland C, Towler MC, Chen S, Smith K et al. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am J Physiol Endocrinol Metab 2009; 296: E1042–E1048.
60. Boon H, Bosselaar M, Praet SF, Blaak EE, Saris WH, Wagenmakers AJ et al. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 2008; 51: 1893–1900.
61. Cuthbertson DJ, Babraj JA, Mustard KJ, Towler MC, Green KA, Wackerhage H et al. 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007; 56: 2078–2084.
62. Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003; 101: 3674–3680.
63. Nafz J, De-Castro Arce J, Fleig V, Patzelt A, Mazurek S, Rosl F. Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1. Biochem J 2007; 403: 501–510.
64. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005; 280: 39582–39593.
65. Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P et al. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS ONE 2009; 4: e7889.
66. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007; 6: 46.
67. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M et al. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 2010; 116: 3023–3032.
68. Montraveta A, Xargay-Torrent S, Lopez-Guerra M, Rosich L, Perez-Galan P, Salaverria I et al. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget 2014; 5: 726–739.
69. Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011; 118: 6399–6402.
70. Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett 2013; 336: 114–126.
71. Chuang HC, Chou CC, Kulp SK, Chen CS. AMPK as a potential anticancer target-friend or foe? Curr Pharm Des 2014; 20: 2607–2618.
72. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661–665.
73. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21: 6082–6090.
74. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733–741.
75. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila Pa) 2010; 3: 1077–1083.
76. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M et al. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 252–258.
77. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16: 839–847.
78. Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958; 21: 485–494.
79. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996; 35: 103–111.
80. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013; 71: 523–530.
81. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010; 70: 1388–1394.
82. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 1993; 27: 43–47.
83. Van Den Neste E, Cazin B, Janssens A, Gonzalez-Barca E, Terol MJ, Levy V et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer Chemother Pharmacol 2013; 71: 581–591.
84. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK dependent apoptosis in prostate cancer cells. Autophagy 2010; 6: 670.
85. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011; 10: 2350–2362.
86. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.
87. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014; 508: 108–112.
88. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA et al. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci USA 2012; 109: 20071–20076.
89. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 2015; 112: 1809–1814.